> ## Content Index
> Fetch the complete content index at: https://www.sanarelab.science/llms.txt
> Use this file to discover other available public pages before exploring further.

# Statins May Prime the Immune System Against Ovarian Cancer, New Preprint Suggests
- URL: https://www.sanarelab.science/statins-immune-ovarian-cancer-preprint-2026/
- Published: 2026-09-25T08:09:16.000Z
- Updated: 2026-09-25T08:09:16.000Z
- Description: Preprint (not peer-reviewed): daily statin use is linked to longer survival in ovarian cancer, and atorvastatin activated cancer-killing immune cells in mice with ovarian tumors.
- Author: Sanare Lab
- Tags: #short-read, News, Research, Repurposed Drugs

Key Takeaway

Daily use of statins (widely used cholesterol-lowering drugs) is linked to longer survival in ovarian cancer, and a new study offers a possible reason: in mice, atorvastatin activated cancer-killing immune cells and extended survival. Note: this is a **preprint, not yet peer-reviewed**.

Researchers led by Juliane Liberto and Tian-Li Wang first confirmed in TriNetX, a large U.S. health-records network, that ovarian cancer patients on daily statins tend to live longer (the summary reports no exact figures). They then tested atorvastatin in mice with ascites-forming ovarian tumors — the fluid-borne spread typical of this cancer — using doses comparable to human prescriptions, unlike the unrealistically high doses common in earlier lab work.

Treated mice lived longer, and their tumors showed a busier immune environment: more activated CD8+ T cells (the immune cells that directly kill cancer), more M1-like macrophages (immune cells switched into tumor-fighting mode), stronger IL-15 signaling (a molecule that stimulates immune cells), and more tertiary lymphoid structures — organized clusters of immune cells inside metastatic tumor tissue.

The authors' take: daily statins may keep the immune system in a more activated state, producing the long-term survival benefit seen in population studies. This is bench evidence, not a clinical recommendation. For context, atorvastatin already features in the [Care Oncology Protocol, which already includes atorvastatin](https://www.sanarelab.science/care-oncology-protocol-coc/); for this cancer type, see [fenbendazole ovarian cancer research](https://www.sanarelab.science/fenbendazole-ovarian-cancer-research/); for dosing discussions, our [dosing calculator](https://www.sanarelab.science/protocol-dosing-workspace/).

## References

1. Liberto JM, Qi S, Rana MM, Shih I-M, Wang T-L. Targeting Tumor Immunity: Statins as a Repurposed Strategy for Preventing Ovarian Cancer Advancement. *bioRxiv* (preprint, not peer-reviewed). 2026 Sep 16\. [doi:10.64898/2026.09.14.751179](https://doi.org/10.64898/2026.09.14.751179?ref=sanarelab.science). [PMID: 42779940](https://pubmed.ncbi.nlm.nih.gov/42779940/?ref=sanarelab.science).

## Medical Disclaimer

This article is for informational purposes only and is not medical advice. The study described is a preprint (not peer-reviewed) combining health-record analysis with animal experiments — not a clinical trial. Never start, stop or change any medication without consulting a licensed healthcare provider.